科济药业-B在最新财年实现亏损幅度显著收窄，主要得益于核心产品泽沃基奥仑赛（Zevorcabtagene Autoleucel）及其他业务板块收入的持续提升。财报数据显示，公司通过优化商业化布局与扩大市场覆盖，有效推动了营收结构的改善。随着CAR-T疗法市场需求的逐步释放，科济药业在研发转化与商业化协同方面展现出强劲动能，为未来盈利能力的进一步修复奠定基础。
科济药业-B在最新财年实现亏损幅度显著收窄，主要得益于核心产品泽沃基奥仑赛（Zevorcabtagene Autoleucel）及其他业务板块收入的持续提升。财报数据显示，公司通过优化商业化布局与扩大市场覆盖，有效推动了营收结构的改善。随着CAR-T疗法市场需求的逐步释放，科济药业在研发转化与商业化协同方面展现出强劲动能，为未来盈利能力的进一步修复奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.